Biographies

Logan K. Wink, MD

Assistant Professor, UC Department of Pediatrics

Phone: 513-636-4611

Email: logan.wink@cchmc.org

Show All

Specialties

Autism spectrum disorders; Angelman syndrome.

Visit the Erickson/Wink lab website.

Biography

Dr. Logan Wink is an assistant professor of Clinical Psychiatry at Cincinnati Children’s Hospital Medical Center. Dr. Wink is a child and adolescent psychiatrist involved in clinical research and clinical care of individuals with developmental disabilities, including Autism Spectrum Disorders and Angelman Syndrome. 

Her primary research focus is improving clinical care of individuals with developmental disabilities through better understanding the pathology of these disorders and improving pharmacologic treatment.

Education and Training

MD: Indiana University School of Medicine, Indianapolis, IN.

Residency: Psychiatry, Indiana University School of Medicine, Indianapolis, IN.

Fellowship: Child Psychiatry, Indiana University School of Medicine, Indianapolis, IN.

Fellowship: Autism and Developmental Disabilities, Indiana University School of Medicine, Indianapolis, IN.

Publications

View PubMed Publications.

Grants

Characterization of Angelman Syndrome. Site Investigator. National Institutes of Health. Jan 2006 - Jun 2016.

A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders. Co-Investigator. Department of Defense. Mar 2010 - Feb 2014.

A Trial of Levodopa in Angelman Syndrome. Site Investigator. United States Food and Drug Administration Office of Orphan Products Development. Jul 2010 - Jun 2014.

Extracellular Signal-Related Kinase Biomarker Development in Autistic Disorder. Co-Investigator. Simons Research Foundation SFARI PILOT AWARD. Sep 2012 - Aug 2014.

A randomized, double blind, placebo-controlled crossover study to evaluate riluzole for treatment of drug-refractory irritability in autism spectrum disorder. Primary Investigator. Pilot Research Award, Center for Clinical and Translational Science and Training. University of Cincinnati Academic Health Center. Jul 2013 - Jun 2014.

Acamprosate in Autistic DisorderCo-Investigator. Autism Speaks. Jan 2013 - Dec 2015. 

Acamprosate in Fragile X SyndromeCo-Investigator. John Merck Fund Translational Research Program Award. Jan 2013 - Dec 2016. 

FRAGILE X CLINICAL AND RESEARCH CONSORTIUM FORWARD REGISTRY AND DATABASECo-Investigator. National Fragile X Foundation/Centers for Disease Control. Sep 2012 - Dec 2014.

A Double Blind, Placebo-Controlled Phase III trial of evaluating the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Fragile X Syndrome in youthCo-Investigator. Seaside Therapeutics. Oct 2012 - Oct 2013.

A Double Blind, Placebo-Controlled Phase II trial of evaluating the Efficacy, Safety, and Tolerability of RO4917523 in the Treatment of Fragile X Syndrome in adolescents and adultsCo-Investigator. F. Hoffmann LaRoche. Sep 2012 - Sep 2013. 

AUTISM SPECTRUM DISORDER GENE EXPRESSION ANALYSIS (STORY) STUDYPrimary Investigator. SynapDx. CCHMC Site.